On August 15, 2023, the Food and Drug Administration (FDA) issued its updated guidance on informed consent for clinical investigations. The newly issued guidance, titled Informed Consent Guidance for IRBs, Clinical Investigators, and Sponsors, lays out the protocols for the informed consent process that should be followed during clinical investigations.
Informed consent is a crucial aspect of the clinical investigation process. It offers prospective subjects the ability to comprehend relevant information concerning a clinical investigation. Moreover, it provides them with the opportunity to ask questions, deliberate on their participation, and voluntarily agree to partake in the study.
The FDA’s updated guidance aims to streamline this process and ensure the rights and welfare of the subjects participating in these investigations are safeguarded. The guidelines are designed to be detailed enough for organizations to apply them in their processes and still flexible enough to accommodate the nuances of different clinical investigations.
With these updated guidelines, the FDA continues its commitment to fostering a more rigorous and ethical approach to clinical investigations. This reflects its ongoing effort to promote trust and transparency within the clinical study community. Final interpretations and potential implications for clinical trials under this updated guidance should be discussed with legal counsel.